PL363679A1 - Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów - Google Patents

Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów

Info

Publication number
PL363679A1
PL363679A1 PL02363679A PL36367902A PL363679A1 PL 363679 A1 PL363679 A1 PL 363679A1 PL 02363679 A PL02363679 A PL 02363679A PL 36367902 A PL36367902 A PL 36367902A PL 363679 A1 PL363679 A1 PL 363679A1
Authority
PL
Poland
Prior art keywords
power
phenyl
novel use
substituted imidazotriazinones
perception
Prior art date
Application number
PL02363679A
Other languages
English (en)
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmut Haning
Afssaneh Rahbar
Tiemo-Joerg Bandel
Wolfgang Barth
Der Staay Franz-Josef Van
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10126198A external-priority patent/DE10126198A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PL363679A1 publication Critical patent/PL363679A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL02363679A 2001-05-09 2002-05-07 Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów PL363679A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10122576 2001-05-09
DE10126198A DE10126198A1 (de) 2001-05-09 2001-05-30 Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinonen
PCT/EP2002/005002 WO2002089808A1 (de) 2001-05-09 2002-05-07 Neue verwendung von 2-phenyl-substituierten imidazotriazinonen

Publications (1)

Publication Number Publication Date
PL363679A1 true PL363679A1 (pl) 2004-11-29

Family

ID=26009261

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363679A PL363679A1 (pl) 2001-05-09 2002-05-07 Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów

Country Status (15)

Country Link
US (1) US20040152700A1 (pl)
EP (1) EP1392314B1 (pl)
JP (1) JP4540295B2 (pl)
CN (1) CN1633298A (pl)
AT (1) ATE348618T1 (pl)
AU (1) AU2002314044B2 (pl)
BR (1) BR0209541A (pl)
CA (1) CA2449163C (pl)
DE (1) DE50209015D1 (pl)
DK (1) DK1392314T3 (pl)
ES (1) ES2278927T3 (pl)
IL (1) IL158738A0 (pl)
MX (1) MXPA03010119A (pl)
PL (1) PL363679A1 (pl)
WO (1) WO2002089808A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395558C (en) * 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7666872B2 (en) 2004-03-05 2010-02-23 Nycomed Gmbh Use for PDE5 inhibitors
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
CN101754756A (zh) * 2007-05-18 2010-06-23 维瓦斯公司 包含磷酸二酯酶-5抑制剂的新组合和它们的用途
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN101965348B (zh) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 伐地那非的制备方法及其中间体
WO2014088326A1 (ko) * 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US3333840A (en) * 1964-11-30 1967-08-01 Harbison Walker Refractories Method of lining a metallurgical furnace and the product thereof
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS61237112A (ja) * 1985-04-12 1986-10-22 Matsushita Electric Works Ltd 電気機器の電力制御回路
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
ES2058527T3 (es) * 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
DK0524180T3 (da) * 1990-04-11 1995-09-04 Upjohn Co Smagsmaskering af ibuprofen ved fluid bedovertrækning
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2395558C (en) * 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19812462A1 (de) * 1998-03-23 1999-09-30 Bayer Ag 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
WO2000025292A1 (en) * 1998-10-27 2000-05-04 Koninklijke Philips Electronics N.V. Driving a matrix display panel
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
MXPA02006240A (es) * 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
US6774128B2 (en) * 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
EP1307201B1 (de) * 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
ATE266407T1 (de) * 2000-10-30 2004-05-15 Lupin Ltd Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil

Also Published As

Publication number Publication date
CA2449163C (en) 2010-07-13
WO2002089808A1 (de) 2002-11-14
DK1392314T3 (da) 2007-03-12
JP2004528363A (ja) 2004-09-16
BR0209541A (pt) 2004-04-20
ATE348618T1 (de) 2007-01-15
EP1392314A1 (de) 2004-03-03
IL158738A0 (en) 2004-05-12
US20040152700A1 (en) 2004-08-05
ES2278927T3 (es) 2007-08-16
EP1392314B1 (de) 2006-12-20
CA2449163A1 (en) 2002-11-14
DE50209015D1 (de) 2007-02-01
MXPA03010119A (es) 2005-03-07
JP4540295B2 (ja) 2010-09-08
AU2002314044B2 (en) 2006-09-21
CN1633298A (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
WO2003055878A8 (de) 2-heteroarylcarbonsäureamide
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
BG108443A (en) Substituted oxazoliidinones for combinational therapy
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
GB0111186D0 (en) Novel compounds
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
IL172773A0 (en) Formulations for the treatment of arhritis conditions
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
WO2003078430A8 (de) Essig- und propionsäureamide
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
WO2003076391A3 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
YU68403A (sh) Upotreba tiolutindioksida i njegovih derivata u proizvodnji leka i postupak za njihovo pripremanje
MY148252A (en) 6-cyclymethyl-and 6-alkylmethyl-substituted pyrazolopyrimidines
WO2003029221A8 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
PL375354A1 (pl) Zastosowanie treosulfanu i jego pochodnych do leczenia stwardnienia rozsianego
MXPA04006120A (es) Piperidin-2,6-dionas sustitudas heterociclicamente en posicion 3.
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
TW200605895A (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
TJ387B (en) The present invention relates to medicine and can be used for treatment of inflammatory process of aleather.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)